Celgene to Buy Receptos for About $7.2 Billion

Health Care Dow Jones Newswires

Celgene Corp. has reached a deal to buy fellow biopharmaceutical company Receptos Inc. for about $7.2 billion, enhancing its portfolio of immune-inflammatory disease treatments with the addition of Ozanimod.

Continue Reading Below

As a result, Celgene is raising its financial targets for 2020, projecting net product sales of more than $21 billion.

The $232-a-share deal offers a 12% premium to Receptos's Tuesday closing price of $207.18.

Receptos's Ozanimod is in development for immune indications including relapsing multiple sclerosis and inflammatory bowel disease.

"Ozanimod is a potentially transformational oral therapy that has demonstrated robust clinical activity" in trials, Celgene said in a statement.

As a result, Celgene is raising its financial targets for 2020, projecting net product sales of more than $21 billion.

Continue Reading Below

Celgene last month agreed to pay Juno Therapeutics Inc. $1 billion as an initial investment in a 10-year collaboration to develop treatments that harness the immune system to fight cancer.

Celgene, based in Summit, N.J., has been on a deal-making spree in recent years as the threat of generic competition to its biggest drug by revenue, Revlimid, has loomed larger. Celgene derived nearly a third of its $7.67 billion in global sales last year from Revlimid, a blood-cancer treatment whose patents are being challenged by generic drug makers.

(By Josh Beckerman)